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of disease in these patients are largely 
influenced by comorbidities, mainly with chronic 
viral hepatitis. The high frequency of co­
infection is caused, first of all, by the same 
transmission mechanisms of these infections, 
especially among injecting drug users (IDUs). 
The proportion of co-infected with HCV in this 
category of patients, intravenous drug users, is 
from 70 to 90%, which causes additional 
problems in treating these diseases.
Interaction between viruses themselves and 
between antiviral drugs is very complex and not 
fully understood. However, the use of HAART 
contributes to a significant increase in life 
expectancy of infected and co-infection with 
HCV, increases the risk of liver damage (it 
accelerates fibrosis, and development of HCC 
and CPU), so mortality from these diseases in 
these patients at the present stage is so high 
that identifies the problem of HCV therapy. It is 
known that the presence of RVR and EVR is the 
most important predictor of HIV-infected 
patient’s treatment efficacy that receive 
concomitant HAART and HCV treatment, and 
the outcome of therapy depends on the use of 
specific drugs from the NRTI group. The aim of 
the study was to determine the effectiveness of 
viral response during the first 12 weeks of 
treatment in patients with chronic hepatitis C 
and HIV infection.
Results: In 2014, 15 patients with HCV in HIV 
infection started the therapy. O f these, there 
were 13 men and 2 women . Genotype 1 HCV 
RNA recorded in 10 patients (66.7%), 3a - in 1 
(6.6%), 3ab in 4 patients (26.7%). The level of 
fibrosis was not determined. Rapid viral 
response was obtained in 4 patients (26.7%), 
early viral response - in 6 (40%). After 24 weeks 
of treatment there were 9 patients (60%) with 
negative PCR, while HCV RNA was determined 
in 2 patients (13.3%), in 1 patient PCR was not 
studied. 10 patients (66.6%) successfully 
completed the treatment with a SVR, 2patients 
are continuing the treatment. 3 patients 
discontinued therapy, of whom 2 - after 12 
weeks of treatment in the absence of any effect 
of antiviral therapy, and 1 because of identified 
comorbidity (active tuberculosis).
C onclus ions: The majority of HIV-infected 
patients receiving HAART, HCV antiviral 
therapy during the first 12 weeks were 
successful, which is extremely important for the 
further prognosis of such patients.
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Background: Common routes of transmission 
of viral hepatitis (B and C), increased number of 
injecting drug users and people having 
unprotected and casual sex led to a significant 
increase in the number of patients with co­
infection of HIV / hepatitis. Therefore, the 
investigation of influence of HIV/viral hepatitis 
co-infection on the course and mortality of both 
viral diseases is important. So, the goal of the 
research was to analyze the prevalence of 
chronic viral hepatitis in patients with HIV 
infection and the impact of HIV / hepatitis co­
infection on mortality rates of patients
Materials & Methods: Retrospective analysis 
of the structure of lethal cases of HIV / AIDS 
during 2011-2013 years was performed; their 
autopsy was conducted in Dnipropetrovsk City 
Hospital #21. In total 250 case histories were 
analyzed.
Results: In 2011, the total number of lethal 
outcomes among hospitalized patients with 
HIV-infection was 72 people. O f these 29 cases 
(40.3%) had co-infection and related liver 
disease (hepatitis B and C). In 2012, the 
number of lethal outcomes was similar (72 
patients), of them 23 cases included co­
infection (31.9%). In 2013 number of lethal 
outcomes among patients with HIV infection 
was significantly less (43 patients), 
nevertheless the proportion of co-infection 
(hepatitis B and C) increased to 41.8% (18 
patients). In majority of cases autopsy was 
established liver injury and fibrosis of different 
degree; cirrhosis was established in 14% of 
cases. In 22% of lethal cases among HIV /
Abstract: 16
Reviews in Antiviral Therapy & Infectious Diseases 2015_7
Abstract 21
hepatitis co-infection liver damage was also 
caused by other reasons: 60% had history of 
drug using, drug toxicity or opportunistic 
infections. 30% of all patients were receiving 
ART, 65% were exposed to TB therapy.
C onclusion : Results of the performed analysis 
show that co-infection of HIV / AIDS with viral 
hepatitis B and C is presented in significant part 
in total mortality structure. This trend is existing 
currently and during recent years. The presence 
of co-infection complicates the course of both 
infections and promotes more rapid progression 
of liver disease. The risk of unfavorable 
outcome is increased by such factors as drug 
use or use of hepatotoxic medicine. It is 
necessary to pay more attention to timely 
diagnosis of HIV / hepatitis B co-infection with 
the purpose of timely treatment of the patients.
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Background: With appearance of antiretroviral 
therapy (ART), the life quality and length of HIV 
infected patients has significantly improved. 
Patients co-infected with HIV / HBV receive 
ART scheme including nucleoside reverse 
transcriptase inhibitors (NRTI), 3TC and TDF, 
with regard to their effect on hepatitis B virus. 
However NRTI are not acting on hepatitis C co­
infection. So, this category of patients requires 
additional antiviral drugs. To plan the financial 
costs of the State Program 'Antihepatitis' and
optimize the management of patients with HIV / 
viral hepatitis co-infection on ART, it is 
necessary to study the spread of these 
conditions and their structure in the cohort.
Materials & m ethods: We analyzed the 
prevalence of serological markers of HBV and 
HCV in a cohort of 501 patients with confirmed 
HIV infection in our clinic.
All patients were conducted clinical and 
laboratory examination, which included 
evaluation (CD4), HIV RNA load, biochemical 
tests, serological markers of opportunistic 
infections and viral hepatitis B (HbsAg, HbeAg, 
Ab HBeAg), C (Ab HCV), Ab to hepatitis D. 
According to WHO classification, 1st disease 
stage was diagnosed in 9 patients (1.8%), 2nd in 
49 (9.8%), 3rd in 164 (32.7%), 4th in 279 (55.7%).
Results: Chronic liver diseases were revealed 
in 167 patients (33.3%): HCV markers in 53 
(10.6%), of hepatitis B in 15 (2.3%), of hepatitis 
B + C in 48 (9.6%), of hepatitis of unknown 
etiology in 44 (8.8%), of liver cirrhosis in 7 
(1.4%). Patients with viral hepatitis B and C 
were divided into 2 groups: receiving ART for at 
least 2 years (1st group, n = 62), without ART 
(2nd group, n = 41). The 1st group patients 
received schemes of ART which included NRTI, 
lamivudine and tenofovir (3TC and TDF) 
Comparative analysis showed that viral markers 
of hepatitis B and C are found in 1st and 2nd 
groups with different frequency. The prevalence 
of chronic hepatitis B markers among 1st group 
is 2.9%, which is almost 9 times lower than in 
the 2nd group (19.1%) (p<0.05). Spread of HCV 
in both groups (36.8% and 41.2% respectively) 
significantly exceeded prevalence of HBV (P 
<0.05). At the same time, the frequency of HCV 
frequency was mainly similar between 1st and 
2nd groups.
C onclusion : It was shown that co-infection of 
HIV / hepatitis occurs in more than 1/3 of 
patients. The structure of HIV / hepatitis co­
infection in the total cohort shows prevalence of 
HCV-infection. Less frequently mixed infection 
(HBV + HCV) and monoinfection are seen. The 
prevalence of chronic hepatitis B was 
significantly lower in patients receiving ART, 
which indicates the effectiveness of ART in two 
directions, to restrict replication of HIV and HBV. 
Obtained results allow more effective 
management of patients with HIV / HCV and/or 
HBV co-infection.
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